Navigation Links
Scientists discover key event in prostate cancer progression
Date:7/23/2009

COLUMBUS, Ohio A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.

The onset of hormone-independent growth marks an advanced and currently incurable stage of prostate cancer.

The study, published in the July 24, 2009, issue of the journal Cell, focuses on androgen receptors, molecules located in the nucleus of cells of the prostate gland and other tissues. Male sex hormones androgens bind with these receptors to activate genes that control cell growth.

The researchers show that in androgen-independent prostate cancer, androgen receptors are reprogrammed to regulate a group of genes involved in a different, later, phase of cell division, triggering rapid cell growth. They further show that a modification of a chief component of the chromosome is responsible for this reprogramming.

"Some late-phase prostate cancer does not require androgen hormones for tumor growth, but it does require androgen receptors," says first author and co-corresponding author Qianben Wang, assistant professor of molecular and cellular biochemistry and a researcher with the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

"Our study reveals the role of androgen receptors in hormone independent prostate cancer, how they become active in that disease and what genes they regulate to promote tumor growth."

The findings provide a better understanding of prostate cancer and could identify new therapeutic targets and lead to new treatments for this lethal stage of the disease, he says.

Prostate cancer is the most frequently diagnosed cancer in men. An estimated 192,280 new cases are expected in the United States in 2009, along with 27,360 deaths from the disease.

To conduct the study, Wang working with corresponding author Dr. Myles Brown, professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, and a group of colleagues used hormone-dependent and hormone independent prostate cancer cell lines, gene expression data and tissue from human tumors.

They showed that in hormone-dependent disease, androgen receptors regulate an early phase of cell cycle. In hormone-independent prostate cancer, however, the receptors are reprogrammed to selectively regulate genes involved in actual cell division, that is, the mitotic phase of the cycle.

A gene called UBE2C was a standout among these genes, and increased expression of that gene correlated with progression to the hormone-independent phase.

Furthermore, a chemical change an epigenetic change in a histone protein associated with that gene enabled androgen receptors to bind with and activate the gene in hormone-independent prostate cancer.

Finally, they show that over-expression of this gene is necessary for the growth of the hormone-independent prostate cancer cells.

"Interestingly," Wang says, "the UBE2C gene is also over-expressed in breast, lung, ovary, bladder, thyroid and esophageal cancers, suggesting that our findings could have wide application."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Scientists Use Non-Embryonic Stem Cells to Create Healthy Mice
2. Scientists Use Adult Stem Cells to Create Healthy Mice
3. Scientists locate disease switches
4. Scientists Reverse Muscular Dystrophy in Mice
5. St. Jude Scientists Discover a New Mechanism Controlling Neuronal Migration
6. Addiction scientists call for end to executions for drug offenders
7. UCLA scientists identify how immune cells may help predict Alzheimers risk
8. Six Scientists Receive Awards for Contributions to Alzheimers Disease Research
9. 6 scientists receive awards for contributions to Alzheimers disease research
10. Two Fred Hutchinson Cancer Research Center Scientists Receive Presidential Early Career Award
11. Scientists Zero In on Elusive Allergy Gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners is ... sequencing and genomics experience, as Vice President of North American Capital Sales at ... for leading the sales team in the commercialization of the HTG EdgeSeq system and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: